Physician profile
Frederick Peng
NPI 1730685777
$3,708.77
in general payments reported to CMS, 2019-2025
20 companies · $1,756 in 2025
The $1,756 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $220 · 2023: $615 · 2024: $1,118 · 2025: $1,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,489.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $916.90 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $546.90 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $506.92 | 2022-2025 | Xifaxan |
| Conmed Corporation | $297.88 | 2022-2025 | Conmed Generators, Conmed Dilation, Conmed Hemostasis |
| Janssen Biotech, INC. | $280.05 | 2024-2025 | Tremfya |
| Madrigal Pharmaceuticals | $192.68 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $157.50 | 2023-2024 | Dificid |
| Novo Nordisk INC | $137.18 | 2025 | Wegovy |
| Gilead Sciences, INC. | $132.23 | 2024-2025 | Vemlidy, Epclusa |
| Genzyme Corporation | $118.47 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $97.18 | 2022-2025 | Ocaliva |
| Pfizer INC. | $79.07 | 2025 | |
| Ardelyx, INC. | $78.67 | 2024-2025 | Ibsrela |
| Boston Scientific Corporation | $48.85 | 2024-2025 | Apollo Esg System, Overstitch Endoscopic Suturing System |
| Celltrion USA INC. | $33.87 | 2025 | Vegzelma |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcresta Therapeutics, INC. | $21.07 | 2023 | Relizorb |
| Phathom Pharmaceuticals, INC. | $19.03 | 2024 | Voquezna |
| Mallinckrodt Hospital Products INC. | $16.06 | 2022 | |
| Lilly USA, LLC | $14.86 | 2025 | Omvoh |
| Redhill Biopharma INC. | $13.40 | 2023 | Talicia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Peng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.